A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2016
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Paclitaxel; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ATEMPT
- 07 Jun 2017 Biomarkers information updated
- 11 May 2015 Planned End Date changed to 1 May 2017, according to to ClinicalTrials.gov record.
- 11 May 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2017, according to to ClinicalTrials.gov record.